Literature DB >> 3755714

The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor.

D J Chaplin, R E Durand, I J Stratford, T C Jenkins.   

Abstract

RSU-1069 is one of a group of compounds of particular interest in radiobiology, since it combines the nitroimidazole ring with a side chain bearing a monofunctional alkylating agent. This compound has been shown to be a potent radiosensitizer both in vitro and in vivo. Furthermore, it has recently been shown to be an effective hypoxic cell cytotoxin in vitro. Our studies have been carried out using the SCCVII squamous carcinoma implanted subcutaneously in C3H mice, using a technique we recently developed which facilitates isolation of tumor cell subpopulations from known locations relative to the tumor blood supply. The response of the separated tumor subpopulations was assessed using a soft agar clonogenic assay. For radiosensitization studies, RSU-1069 was administered i.p. at 0.5 mumol/g 20 min before irradiation and the tumors excised 20 min after irradiation. For toxicity studies, tumors were excised 16-18 hr after RSU-1069 administration. The results obtained to date clearly demonstrate that RSU-1069 is an efficient hypoxic cell radiosensitizer and cytotoxin in this murine tumor and has little effect on well perfused (i.e., oxic) cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3755714     DOI: 10.1016/0360-3016(86)90233-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Effect of etoposide, carmustine, vincristine, 5-fluorouracil, or methotrexate on radiobiologically oxic and hypoxic cells in a C3H mouse mammary carcinoma in situ.

Authors:  C Grau; J Overgaard
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

Review 3.  Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.

Authors:  J C Bremner
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

4.  Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo: importance of nicotinamide dose and pre-irradiation breathing time.

Authors:  D J Chaplin; M R Horsman; D W Siemann
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

5.  Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions.

Authors:  K H Wong; C J Koch; C A Wallen; K T Wheeler
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

Review 6.  Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy.

Authors:  Beom-Ju Hong; Jeongwoo Kim; Hoibin Jeong; Seoyeon Bok; Young-Eun Kim; G-One Ahn
Journal:  Radiat Oncol J       Date:  2016-12-28

7.  Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT).

Authors:  D J Chaplin
Journal:  Br J Cancer       Date:  1986-11       Impact factor: 7.640

8.  Chemosensitization by misonidazole in CCNU-treated spheroids and tumours.

Authors:  R E Durand; D J Chaplin
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.